Your session is about to expire
← Back to Search
ALRN-6924 for Small Cell Lung Cancer
Phase 1
Waitlist Available
Research Sponsored by Aileron Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology. Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available for p53 mutation analysis. FDA approved liquid biopsies are also acceptable.
Presence of one or more p53 mutations.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 19 months
Awards & highlights
Study Summary
This trial is studying a drug to see if it can help prevent side effects from chemotherapy in patients with lung cancer.
Eligible Conditions
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 19 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 19 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Phase 1b Part 1 SCLC
Phase 1b Part 2 NSCLC
Trial Design
3Treatment groups
Experimental Treatment
Group I: Part 2 NSCLC: Placebo+Carboplatin+PemetrexedExperimental Treatment3 Interventions
Group II: Part 2 NSCLC: ALRN-6924+Carboplatin+PemetrexedExperimental Treatment3 Interventions
Group III: Part 1 SCLC: ALRN-6924+TopotecanExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALRN-6924
2018
Completed Phase 2
~230
Placebo
1995
Completed Phase 3
~2670
Carboplatin
2014
Completed Phase 3
~6670
Pemetrexed
2014
Completed Phase 3
~5250
Topotecan
2017
Completed Phase 3
~2400
Find a Location
Who is running the clinical trial?
Aileron Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
264 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger